Novo Nordisk (NOVOB DC) is seeking to widen access to obesity treatments in Japan by targeting patients willing to pay out of pocket for GLP-1 drugs such as Wegovy, Bloomberg reports

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

CK Hutchinson (0001 HK) FY (HKD): Net Income 11.84bln (exp. 21.74bln), Total Revenue 507.3bln (exp. 483.5bln), EBIT 57.6bln (exp. 59.3bln)

China Jan-Feb fiscal expenditures +3.6% Y/Y; fiscal revenues +0.7% Y/Y

Novo Nordisk (NOVOB DC) is seeking to widen access to obesity treatments in Japan by targeting patients willing to pay out of pocket for GLP-1 drugs such as Wegovy, Bloomberg reports

China's Industry Minister says China is to focus on advanced basic materials, key strategic materials, and frontier new materials; calls for exploring AI application in materials research, testing, and production

Saudi Arabia says it has intercepted a missile heading towards Yanbu port

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.
  • The company will work with physicians and patients on self-funded treatment pathways, its Japan head Keisuke Kotani said.

Context

Novo Nordisk's initiative to expand access to obesity treatments in Japan represents a strategic move to tap into a lucrative market segment willing to pay out of pocket for GLP-1 drugs like Wegovy. This could enhance their revenue streams and market presence in a country with increasing obesity rates. Moreover, collaborating with healthcare providers could foster stronger relationships and potentially set a precedent for similar strategies across other regions.

Related headlines

The feed had this first.

Use the Platform